May 09, 2025 -- Garuda Therapeutics (“Garuda”), a biotechnology company developing off-the-shelf hematopoietic stem cell (HSC) therapies, today announced that it has changed its name to Stratus Therapeutics, Inc. (“Stratus”). The new name reflects the company’s commitment to pioneering full hematopoietic system renewal through its novel platform, Stratus Prime™, and lead product candidate, ST-101. Stratus Therapeutics is the only company developing on-demand Prime HSCs™ and Prime HPCs™ to rest

May 09, 2025 -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from the first independent validation of the recently published Collaborative Ocular Oncology Group Study No. 2 (COOG2.1) by Harbour et al.1 The data, from a real-world cohort of 1,297 patients with uveal melanoma (UM), was presented at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting in Salt Lake City.

May 09, 2025 -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, presented results from the Phase 2b SYMMETRY trial demonstrating the potential of efruxifermin (EFX) to improve fibrosis in compensated cirrhosis (F4) caused by metabolic dysfunction-associated steatohepatitis (MASH), in a late-breaking oral presentation at the European Association for the Study o

Conduit secures a composition of matter patent from the Korean Intellectual Property Office for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders, positioning the Company for clinical development and strategic partnerships. May 09, 2025 -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals", "Conduit" or the “Company”) today announces that the Korean Intellectual Property Office (KIPO) has granted the composition of matter patent for its lead ass

May 09, 2025 -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, today announced results of a PET scan showing a marked reduction in microglia activation associated with neuroinflammation in a patient suffering from moderate Alzheimer's disease (AD) who was treated for three months with intranasa

Prof. Lars Zender’s featured talk described HepaRegeniX’s lead candidate and its potential in increasing liver regeneration, from initial target discovery and drug development towards Phase Ia clinical trial results May 8, 2025 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage company advancing novel therapies to treat acute and chronic liver diseases, announced that the company’s co-founder, Prof. Dr. med. Lars Zender, gave the Karl Wilhelm von Kupffer Basic Science State-of-the-Art plenary

New patent filing secures composition of matter protection for AZD5904, a potent myeloperoxidase inhibitor in Conduit’s pipeline, unlocking up to 20 years of new IP runway and enabling enhanced formulation strategies to target a broad range of diseases. May 08, 2025 -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals", "Conduit" or the “Company”) today announces the filing of a new composition of matter patent covering a novel solid form of AZD5904, a clinical-stage myeloper

May 08, 2025 -- Yamo Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to treating the core symptoms of autism spectrum disorder (ASD), today announced positive Phase 2 results for L1-79, presented at the International Society for Autism Research (INSAR) 2025 Annual Meeting. The 12-week randomized, double-blind, placebo-controlled crossover study (n = 58, ages 12-21) showed statistically significant and clinically meaningful improvements in the Vineland-3 Socialization Sta

- Patients treated with VCN-01 (zabilugene almadenorepvec) plus gemcitabine/nab-paclitaxel standard-of-care (SoC) chemotherapy had increased overall survival, progression free survival, and duration of response compared to patients treated with gemcitabine/nab-paclitaxel SoC - - VCN-01 was well-tolerated, with transient and reversible adverse events (AEs), meeting primary safety endpoint - - Greater differences between the treatment arms were observed in patients receiving 2 doses of VCN-01 - -

The Independent Data Monitoring Committee (IDMC) has recommended to continue the study as planned as there are no safety concerns seen in the data reviewed Continued momentum with completed patient enrollment for the 6-week interim analysis (N=24) and over two-thirds enrollment completed for the overall trial Results on track for interim data in Q2 2025 and topline data in Q3 2025 Management releases “What This Means” segment discussing the interim biomarker data; Access Here May 08, 2025 (GL